Pharmaceutical

MDCE Powers Up with Patent-Pending AI Tech, Auction Expansion & Share Restructure Plan

Game-Worn Icons. AI Innovation. Big Restructure. MDCE Is On a Mission. MESA, ARIZONA / ACCESS Newswire / August 8, 2025…

5 months ago

Modular Medical Announces Next-Generation Pivot Insulin Pump at ADCES and Introduction of Level Ex Gamified Training Collaboration

-Debuting a "coming soon" campaign for tubeless Pivot patch pump- Expects special 510(k) filing for Pivot product in October- Will…

5 months ago

Ultrack Systems Inc. (OTC: MJLB) Adds PUR Botanicals as Strategic Partner in PUR Rx Joint Venture: A Fully Vertically Integrated Natural Health Pharmacy Targeting Explosive Growth

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB), a Canadian-based leader in wellness-focused technology and compliance-driven…

5 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected…

5 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at…

5 months ago

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

5 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a…

5 months ago

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on…

5 months ago

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance…

5 months ago

Vistin Pharma ASA: Invitation to Q2 2025 conference call

Oslo, Norway, 08 August 2025 Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th…

5 months ago